Cosmo Bio Co

Cosmo Bio Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 108.93 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 9.54 % — a change of 1,041.57% (higher).

FCF Conversion

108.93 %

YoY

1,041.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cosmo Bio Co is 2025 108.93 % . FCF Conversion Rate (FCF/EBITDA) of Cosmo Bio Co was 2024 9.54 % . It decreases by 1,041.57% higher compared to the previous year.

The Cosmo Bio Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
329.62 JPY
Jan 1, 2019
163.29 JPY
Jan 1, 2020
109.50 JPY
Jan 1, 2021
68.79 JPY
Jan 1, 2022
34.82 JPY
Jan 1, 2023
143.89 JPY
Jan 1, 2024
9.54 JPY
Jan 1, 2025
108.93 JPY
The Cosmo Bio Co FCF Conversion history
YEARFCF ConversionYoY
108.93 %+1,041.57%
9.54 %-93.37%
143.89 %+313.29%
34.82 %-49.39%
68.79 %-37.17%
109.50 %-32.94%
163.29 %-50.46%
329.62 %-300.30%
-164.56 %-231.13%
125.49 %+260.78%
34.78 %-71.35%
121.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

FCF Conversion Rate (FCF/EBITDA) of Cosmo Bio Co is 108.93 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cosmo Bio Co changed from 9.54 % to 108.93 %, representing a 1,041.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co